The current market presents a complex mix of opportunities and risks. Check out my picks that include high-quality, ...

AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...

AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stages of its trials. The ...

AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That' ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost any ...

The healthcare product conglomerate in 2013 year spun out its research pharmaceuticals business into stand-alone company Abbvie, leaving behind 4 restructured business divisions: diagnostics ...

Not only one new race, but a whole new continent. The TCS Sydney Marathon presented by Asics is now the seventh Abbott World Marathon Majors race. Beginning in 2025, the Australian city will join the ...